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Cachexia means any general reduction in vitality and 
strength of body and mind resulting from any debilitating 
chronic disease. Cachexia is defined as loss of weight, 
muscle atrophy, fatigue, weakness, and loss of appetite in 
someone who is not actively trying to lose weight. These 
features markedly distinguish cachexia from starvation. 
Cachexia can be a sign of various underlying disorders. 
Physicians confronted with cachexia generally consider 
the possibility of cancer, certain infectious diseases such 
as tuberculosis or AIDS, parasitic diseases, autoimmune 
disorders, or chronic heart failure. Cachexia physically 
weakens patients to a state of immobility stemming from 
loss of appetite, asthenia, and anemia. The response to 
standard treatments is poor [1]. The above sounds 
straightforward enough. However, in PubMed, about 
4,500 papers have been published on cachexia; 
interestingly, >1,000 of these papers are reviews. Such a 
relationship raises suspicion that little is known about the 
subject. Weber et al. [2], in this issue, introduce a novel 
inverse marker of clinical muscle wasting, namely, the 
measurement of plasma myoglobin concentration. Their 
report is immediately disconcerting, as the title of their 
paper ends in a question mark, implying a lack of self-
confidence on behalf of the authors. However, the entire 
cachexia field is riddled with question marks. 
Weber et al. studied 17 cancer patients, the prototype 
patients exhibiting cachexia. The patients had lost >20% 
of their body mass without intending to do so. A suitable 
matched control group of 27 subjects was recruited who 
had lost no weight. Plasma myoglobin, creatine kinase, 
quadriceps muscle cross-sectional area (by magnetic 
resonance imaging), muscle morphology from biopsies of 
the Vastus lateralis, body cell mass by impedance, and 
maximal oxygen uptake (VO2 max) were all measured in 
these patients and control subjects. To no surprise, 
myoglobin, muscle cross-sectional area, body cell mass, 
and VO2 max were all lower in cachexic cancer patients 
than in healthy controls. However, in a multiple-regression 
analysis, myoglobin (hypomyoglobinemia) won out over 
other indicators (27 μg/dl vs 42 μg/dl); or did it? The 
authors found that myoglobin was directly correlated with 
cross-sectional muscle mass and was better than 
reduced creatine kinase in this regard, although the 
magnitude of the creatine kinase reduction was greater. 
The fact that creatine kinase and myoglobin were not 
elevated is of some mechanistic interest, since active 
muscle destruction would have featured elevation of both 
myoglobin and creatine kinase. Weber et al. [2] performed 
muscle biopsies on 11 patients and 15 control subjects. A 
marked size reduction in type 1 and 2 fibers occurred in 
the cachexic patients that corresponded to the reduction 
in cross-sectional area and correlated significantly with 
the reduced myoglobin levels. 
What causes cachexia anyway? Are the diverse chronic 
(or not so chronic) cachexia conditions related? The 
cachexic patients presented by Weber et al. [2] all had 
cancer. Skipworth et al. [3] recently reviewed cancer 
cachexia. They stressed the role of host–tumor 
interaction, particularly pro-inflammatory cytokines. Tumor 
cells release cytokines and other factors locally to 
promote inflammation and thereby activate a local 
response. For instance, proteolysis-inducing factor (PIF) is 
a sulphated glycoprotein that produces muscle wasting in 
tumor-free mice when injected. The material has been 
identified in patients with pancreatic, breast, ovarian, lung, 
colon, rectum, and liver cancers. PIF may activate the 
ubiquitin–proteasome pathway by a nuclear factor kappaB 
(NF-κB) related mechanism. Lipid-mobilizing factor (LMF) 
is another cachexia protein produced by tumors. LMF 
increases lipid oxidation via induction of uncoupling 
protein expression, perhaps by interacting with the β3 
adrenoceptor. 
Tumor products activate host cells. The activated host 
cells then initiate their own cytokine cascade, thereby 
inducing the hepatic acute phase protein response 
(APPR). APPR induction appears to be primarily an 
interleukin-6 (IL-6)-driven mechanism; however, tumor 
necrosis factor-alpha (TNF-α), IL-2, IL-8, interferon-
gamma (IFN-γ), parathyroid hormone-related peptide 
(PTHrP), and macrophage migratory inhibitory factor 
(MIF) also participate. Other cytokines such as IL-4, IL-10, 
and IL-13 have anti-inflammatory effects and are thought 
to repress cachexia. IL-15 has anabolic effects on skeletal 
muscle through the direct inhibition of muscle proteolysis. 
The hepatic APPR includes a large number of “positive” 
acute-phase proteins, such as C-reactive protein (CRP) 
and fibrinogen. CRP correlates with weight loss, 
hypermetabolism, anorexia, and reduced survival. On the 
other hand, the circulating levels of “negative” acute-
phase proteins such as albumin decrease. Cancer 
cachexia is also associated with a neuroendocrine stress 
response. Weight-losing cancer patients exhibit insulin 
resistance, dysregulation of the autonomic nervous 
system, and sympathetic activation. A schematic 
suggested by Skipworth et al. [3] is given in Fig.1. 
Another chronic cachexia condition is provoked by chronic 
heart failure (CHF). CHF patients who involuntarily lose 
non-edematous weight >6% of their previous normal 
weight are at substantially greater risk for subsequent 
mortality [4]. The parameter has a very high sensitivity–
specificity product. CHF cachexia correlates rather poorly 
with ejection fraction or the New York Heart Association 
functional cardiac classification. Proinflammatory 
cytokines, TNF-α, IL-1, IL-6, and others again appear, as 
does the hepatic APPR. In CHF, there are no invading 
tumor cells that release mediators, although 
catecholamines, cortisol, natriuretic peptides, and heat-
shock proteins have been implicated. An imbalance 
between anabolic and catabolic pathways becomes 
established that involves numerous hormone systems, 
including neuropeptide Y, insulin, cortisol, leptin, and 
ghrelin. A decrease in food intake alone does not trigger 
the wasting process. The initial triggers are unknown. 
A related, more short-term condition developing over days 
to weeks is critical illness myopathy (CIM). This condition 
was first identified in intensive care unit patients who had 
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developed the systemic inflammatory response syndrome 
(SIRS) usually in the framework of sepsis [5]. CIM 
patients commonly develop encephalopathy and 
neuropathy, as well as a diffuse, flaccid weakness of 
limbs and diaphragm. CIM is associated with SIRS, 
multiple organ failure, and corticosteroid and 
neuromuscular blocking agent administration. CIM 
features bioenergetic failure, mitochondrial dysfunction, 
inflammatory mediator-related proteolysis, hormonal 
dysregulation with glucose toxicity, myosin loss, and 
markedly increased total muscle catabolism. The triggers 
are unknown. The ubiquitin–proteosome pathway has 
been implicated along with cyclooxygenase activation, 
altered glucose transporter expression, MyoD 
suppression, impaired respiratory chain enzymes, ATP 
depletion, and insulin resistance. As mediators, TNF-α, 
IFN-γ, IL-1, IL-6, CRP, and the regulatory transcription 
factor NF-κB again prominently appear. 
The cachexia syndromes are diverse diseases with 
certain features that suggest a final common pathway. 
The pathway leads to marked muscle wasting, systemic 
inflammation, hepatic APPR, and disturbed metabolism. 
The pathophysiological changes are tightly regulated by 
the same cytokines. Thus far, the final common pathway 
has not proved to be a therapeutic avenue. Elucidation of 
the triggers would appear more promising. The muscle 
biopsies performed by Weber et al. [2] could be helpful in 
this regard. Possibly, very early changes that could be 
identified by serial biopsy might be helpful. Such biopsies 
could be coupled with metabolic studies that can be 
discerned at the tissue level by microdialysis and similar 
techniques. Magnetic resonance spectroscopy coupled 
with imaging could be applied. The area is ripe for novel 
patient-oriented translational research. 
 
Respectfully, 
Friedrich C. Luft 
 
 
Fig.1: Pro-inflammatory cytokines induce muscle wasting 
either directly or indirectly. The process involves a cytokine 
storm, anorexia, metabolic disturbances, and enhanced 
catabolism, as well as acute-phase response proteins and 
their effects [3] 
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